Drug Delivery · Nov 4, 2026

Hepa-SENS: ASGPR-mediated hepatocyte delivery and attenuated unwanted immune recognition for nucleic acid therapeutics

By Kim GY, Lee S, Kim H et al.

An optimal nucleic acid delivery system for hepatic therapeutics should demonstrate consistent pharmacological performance across both normal and diseased hepatic microenvironments, enabling repeated administration with favorable safety profiles. Given the disease-sensitive and relatively low expression of low-density lipoprotein receptor (LDLR) on hepatocytes and compared to the abundant and disease-resilient expression of asialoglycoprotein receptor (ASGPR), ASGPR-mediated drug delivery presents a compelling strategy for liver diseases. Here, we introduce Hepa-SENS, a next-generation polymer-lipid hybrid nanoparticle platform enabling robust ASGPR-mediated hepatocyte delivery without ligand conjugation. Its biodistribution, hepatocyte selectivity, receptor dependence, repeated-dose activity, and therapeutic performance were evaluated in healthy and fibrotic mouse liver models. Hepa-SENS demonstrates strong, hepatocyte-selective transgene expression of mRNA payload preserved under disease conditions, such as high-fatty liver and liver fibrosis, and across multiple species, including non-human primates. In long-term repeat-dose regimens, Hepa-SENS sustained mRNA-driven protein expression without inducing antibodies to the delivery system, enabling greater consistency than conventional lipid nanoparticles (LNPs). In fact, in a liver fibrosis mouse model, where a reduction of LDLR is observed as fibrosis develops, Hepa-SENS outperformed conventional LNPs in delivering therapeutic hepatocyte nuclear factor 4 alpha mRNA and attenuating disease progression. In conclusion, Hepa-SENS represents a robust and versatile delivery platform for nucleic acid therapeutics targeting hepatocytes under disease-relevant conditions via ASGPR-dependent mechanisms. Its repeated-dosing-compatible design supports durable treatment strategies for chronic liver diseases.

doi.org/10.1080/10717544.2026.2752664Open accessPubMed 42978531Interventions

AgingResearch.News